RecruitingOverweightObesity

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Eligible age

18+ yrs

Accepts

All genders

Locations

25 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

Sponsor: Eli Lilly and Company

You may qualify if…

✓ Have type 2 diabetes
✓ Are on stable treatment for type 2 diabetes for at least 90 days prior to screening
✓ Have a BMI ≥ 27 kg/m2
✓ Have a stable body weight (\<5% body weight change) for 90 days prior to screening

You may not qualify if…

✕ Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
✕ Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
✕ Have type 1 diabetes
✕ Have taken any of the following antihyperglycemic medications within 90 days before screening:
✕ amylin analogs
✕ glucagon-like peptide-1 (GLP-1) receptor agonists
✕ glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP) receptor agonists, or
✕ insulin